Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated witn imatinib mesylate [2]

Leukemia

Volumn 17, Issue 2, 2003, Pages 461-463

  Schoch, C ^a   Haferlach, T ^a   Kern, W ^a   Schnittger, S ^a   Berger, U ^b   Hehlmann, R ^b   Hiddemann, W ^a   Hochhaus, A ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; BUSULFAN; HYDROXYUREA; IMATINIB; INTERFERON;

CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHROMOSOME BANDING PATTERN; CHROMOSOME DELETION; CHROMOSOME TRANSLOCATION; CHROMOSOME TRANSLOCATION 17; CHROMOSOME TRANSLOCATION 19; CHROMOSOME TRANSLOCATION 2; CHROMOSOME TRANSLOCATION 22; CHROMOSOME TRANSLOCATION 7; CHROMOSOME TRANSLOCATION 9; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; DRUG RESPONSE; HUMAN; KARYOTYPING; LETTER; MAJOR CLINICAL STUDY; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; TRISOMY 8;

EID: 0037330989     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402813     Document Type: Letter

References (10)

1. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-1037.
2. Kantarjian H, Sawyers CL, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U, Talpaz M, Druker BJ, for the International STI571 CML Study Group. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346: 645-652.
3. Hochhaus A, Kreil S, Corbin A, La Rosee P, Lahaye T, Berger U, Cross NC, Linkesch W, Druker BJ, Hehlmann R, Gambacorti-Passerini C, Corneo G, D'Incalci M. Roots of clinical resistance to STI-571 cancer therapy. Science 2001; 293: 2163.
4. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876-880.
5. Chase A, Huntly BJP, Cross NCP. Cytogenetics of chronic myeloid leukemia. Best Pract Res Clin Hematol 2001; 14: 553-571.
6. Hild F, Freund M, Fonatsch C. Chromosomal aberrations during interferon therapy for chronic myelogenous leukemia. N Engl J Med 1991; 325: 132.
7. Johansson B, Fioretos T, Billström R, Mitelman F. Aberrant cytogenetic evolution pattern of Philadelphia-positive chronic myeloid leukemia treated with interferon-α. Leukemia 1996; 10: 1134-1138.
8. Kantarjian HM, Smith TL., O'Brien S, Beran M, Pierce S, Talpaz M. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service. Ann Intern Med 1995; 122: 254-261.
9. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese DJ, Ford JM, Capdeville R, Talpaz M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344: 1038-1042.
10. Sokal JE, Gomez GA, Baccarani M, Tura S, Clarkson BD, Cervantes F, Rozman C, Carbonell F, Anger B, Heimpel H, Nissen NI, Robertson JE. Prognostic significance of additional cytogenetic abnormalities at diagnosis of Philadelphia chromosome-positive chronic granulocytic leukemia. Blood 1988; 72: 294-298.